Open AccessA Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis
Author(s) -
Sang-A Choi,
SeungGeun Lee,
Sang Heon Song,
JiMin Kim,
Hye-Yoon Jang,
WooJin Jung,
Jonghyun Choi,
Young Eun Park,
Seong-Hu Park,
JoungWook Lee,
JunHee Lee,
Seung-Hoon Baek,
Geun-Tae Kim
Publication year - 2013
Publication title -
journal of rheumatic diseases
Language(s) - English
Resource type - Journals
eISSN - 2233-4718
pISSN - 2093-940X
DOI - 10.4078/jrd.2013.20.6.361
Subject(s) - etanercept , medicine , ankylosing spondylitis , peritoneal dialysis , nephrotoxicity , tumor necrosis factor alpha , infliximab , nonsteroidal , dialysis , pharmacology , gastroenterology , kidney
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFα) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFα agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFα agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom